Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0487-0111 in Type 2 Diabetes
NCT06542874Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2024
- Primary completion
- Oct 2025
- Modality
- Peptides, Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of amycretin in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Aug 2024; status: completed.
02
Drugs
amycretin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06542874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06542874.